SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of therapeutic DNA vaccines for cancers and infectious diseases using its electroporation-based delivery platform, announced today the online availability of a peer-reviewed scientific paper, “DNA vaccines: precision tools for activating effective immunity against cancer”, in the February 2008 issue of Nature Reviews Cancer. The paper is authored by Jason Rice, Christian H. Ottensmeier and Freda K. Stevenson of the University of Southampton (UK). Dr. Ottensmeier and Dr. Stevenson are investigators for a prostate cancer Phase I/II clinical study assessing a DNA vaccine delivered using Inovio’s electroporation-based DNA delivery technology, which is intended to enable and enhance the potency of DNA vaccines.
